Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial
Mikaël Mazighi(Inserm), Mathieu Zuber(Université Paris Cité), Francisco Macian-Montoro(Inserm), Angelika Alonso, Andrea Comenducci(Paris Biotech Santé), Joaquı́n Serena(Universität Hamburg), Jaime Masjuán(Universidad de Alcalá), Robin Lemmens(VIB-KU Leuven Center for Microbiology), James C. Grotta(Memorial Hermann), Yannick Plétan(Paris Biotech Santé), Sylvie De Raedt(Vrije Universiteit Brussel), Philippe Lyrer(University of Basel), Sébastien Richard(Inserm), André Peeters(Cliniques Universitaires Saint-Luc), José Ignacio Tembl, Michaël Obadia(Inserm), Adeline Meilhoc(Paris Biotech Santé), Martin Köhrmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Martine Jandrot‐Perrus(Inserm), Dimitri Hemelsoet(Ghent University Hospital), Johann Pelz(University Hospital Leipzig), Sophie Binay(Paris Biotech Santé), Danilo Toni(Sapienza University of Rome), Anouar Sari(Paris Biotech Santé), Charlotte Cordonnier(Inserm), Gilles Avenard(Anna Needs Neuroblastoma Answers), Igor Sibon(Inserm), Émilie Doche, Stéphane Vannier, Jörg Berrouschot(Klinikum Altenburger Land), Carlos A. Molina(Vall d'Hebron Hospital Universitari), Jean‐Marie Grouin(Université de Rouen Normandie), Jean François Albucher(Université Toulouse III - Paul Sabatier), Tomás Segura(Complejo Hospitalario Universitario de Albacete), Philippe Desfontaines, Peggy Reiner(Hôpital Lariboisière)
Cited by 64
Related Papers
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k